References
- Andersen K W, Mouridsen HT. Danish Breast Cancer Cooperative Group (DBCG). Acta Oncol 1988; 27: 627–47
- Dombernowsky P, Hansen P S, Mouridsen H T, Overgaard M, Rose C, Zedeler K. Randomized trial of adjuvant CMF + Radiotherapy vs CMF alone vs CMF + Tamoxifen in pre- and menopausal stage II breast cancer (Abstract). Eur J Cancer 1994, 30: 28, (Suppl 2)
- Overgaard M, Hansen P S, Rose C, et al. Postmastectomy radiotherapy and adjuvant systemic treatment in high-risk cancer patients. (Abstract). Eur J Cancer 1994, 30: 28, Suppl 2
- Rose C, Hansen P S, Dombernowsky P, et al. A randomized DBCG trial of adjuvant Tamoxifen + Radiotherapy vs. Tamoxifen alone vs. Tamoxifen + CMF in postmenopausal breast cancer patients with high risk recurrence. (Abstract). Eur J Cancer 1994, 30: 28, (Suppl 2)
- Dombernowsky P, Brincker H, Hansen M, et al. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group trials 77-B and 82-B. Acta Oncol 1988; 27: 691–7
- Overgaard M, Juul Christensen J, Johansen H, et al. Postmastectomy irradiation in high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group trials. Acta Oncol 1988; 27: 707–14
- Mouridsen H T, Rose C, Overgaard M, et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncol 1988; 27: 699–705
- Kamby C. The pattern of metastases in human breast cancer: Methodological aspects and influence of prognostic factors. Cancer Treatment Reviews 1990; 17: 37–61
- Zedeler K. Assessment and presentation of survival experience in the Danish Breast Cancer Cooperative Group. Acta Oncol 1988; 27: 649–62
- Vantongelen K, Steward W, Blackledge G, Verweij J, Van Oosterom A. Treatment-related variables and data acquisition in chemotherapy. Eur J Cancer 1991; 27: 201–7
- Vantongelen K, Rotmensz N, van der Schueren E. Quality control of validity of data collected in clinical trials. Eur J Cancer Clin Oncol 1989; 25: 1241–7